Gilead Partnership With Arcus Brings PD-1, TIGIT Assets To Its IO Portfolio
The 10-year partnership brings Arcus up-front funding with ample earnout opportunities, while Gilead gets extensive opt-in rights and an equity stake it can increase – and potentially a wholly owned dual checkpoint combination.
You may also be interested in...
Gilead Adds Inflammation Targets To Its 2020 R&D Collaboration With Arcus
Deal Snapshot: Already partnered on an anti-TIGIT drug and other immuno-oncology candidates, the firms will team up further on four targets in inflammatory disease.
Gilead Keeps Focus On HIV, Long-Acting Drugs And Growth Through Oncology
Even with top-seller Biktarvy and its preventive therapy, Descovy, protected beyond this decade from generics, Gilead is investing aggressively in long-acting HIV candidates and its oncology pipeline.
Gilead Goes Full Steam Ahead In Oncology With Big Lung Cancer Push
The company has eight lung cancer trials running and plans for nine by the end of the year, including five with Trodelvy alone. Gilead is also looking ahead to an FDA verdict on lenacapavir.